Key result
The CCL2 -2518 A allele confers increased susceptibility to chronic Chagas cardiomyopathy in T. cruzi-infected individuals (OR 1.9; 95% CI 1.3-2.9; P=0.001).
Why the study?
Is the CCL2 -2518A/G gene polymorphism associated with the development of chronic Chagas cardiomyopathy in individuals infected with Trypanosoma cruzi?
Case-Control (n=245)
Is the CCL2 -2518A/G gene polymorphism associated with the development of chronic Chagas cardiomyopathy in individuals infected with Trypanosoma cruzi?
Odds Ratio: 1.9 (95% CI 1.3–2.9)
p-value: p=0.001
The CCL2 -2518AA genotype acts as a genetic modifier that significantly increases the risk of developing chronic Chagas cardiomyopathy in patients infected with Trypanosoma cruzi.
Authors
No takes yet. Share an insight, caveat, or question.
May support closer monitoring in susceptible patients; hypothesis-generating and should not yet change practice.
Ramasawmy et al. (2006) conducted a case-control in Chagas disease (n=245). CCL2 -2518A/G polymorphism (A allele) vs. G allele was evaluated on Chronic Chagas cardiomyopathy (CCC) (OR 1.9, 95% CI 1.3-2.9, p=0.001). The CCL2 -2518 A allele confers increased susceptibility to chronic Chagas cardiomyopathy in T. cruzi-infected individuals (OR 1.9; 95% CI 1.3-2.9; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: